Corcept Therapeutics Incorporated
DE ˙ DB ˙ US2183521028
63,98 € ↑2,18 (3,53%)
2026-06-04
AKTIENPREIS
SecurityDE:HTD / Corcept Therapeutics Incorporated
InstitutionM&t Bank Corp
Latest Disclosed Ownership8,459 shares
Latest Disclosed Value $ 340,983
M&t Bank Corp reports 28.05% decrease in ownership of HTD / Corcept Therapeutics Incorporated

On May 12, 2026 - M&t Bank Corp filed a 13F-HR form disclosing ownership of 8,459 shares of Corcept Therapeutics Incorporated (DE:HTD) valued at $291,751 USD as of March 31, 2026. The entity filed a previous 13F-HR/A on January 30, 2026 disclosing 11,756 shares of Corcept Therapeutics Incorporated. This represents a change in shares of -28.05% during the quarter. The current value of the position is $541,207 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-12 2026-03-31 13F CORCEPT THERAPEUTICS COM 218352102 8,459 -3,297 -28.05 341 -16.87 0.0003
2026-01-30 2025-12-31 13F/A-1 CORCEPT THERAPEUTICS COM 218352102 11,756 5,662 92.91 409 -19.17 0.0013
2026-01-28 2025-12-31 13F CORCEPT THERAPEUTICS COM 218352102 13,240 7,146 1,840 0.0011
2025-11-14 2025-09-30 13F CORCEPT THERAPEUTICS COM 218352102 6,094 495 8.84 507 23.41 0.0017
2025-08-13 2025-06-30 13F CORCEPT THERAPEUTICS COM 218352102 5,599 -40 -0.71 411 -36.24 0.0014
2025-04-30 2025-03-31 13F CORCEPT THERAPEUTICS COM 218352102 5,639 -3,530 -38.50 644 39.48 0.0023
2025-02-06 2024-12-31 13F CORCEPT THERAPEUTICS COM 218352102 9,169 -1,249 -11.99 462 -4.36 0.0015
2024-11-19 2024-09-30 13F/A-1 CORCEPT THERAPEUTICS COM 218352102 10,418 -534 -4.88 483 35.77 0.0016
2024-11-15 2024-09-30 13F CORCEPT THERAPEUTICS COM 218352102 10,418 -534 483 0.0003
2024-07-31 2024-06-30 13F CORCEPT THERAPEUTICS COM 218352102 10,952 -618 -5.34 356 21.99 0.0012
2024-05-07 2024-03-31 13F CORCEPT THERAPEUTICS COM 218352102 11,570 11,570 291 0.0010
2019-02-01 2018-12-31 13F CORCEPT THERAPEUTICS COM 218352102 0 -16,077 -100.00 0 -100.00
2018-11-09 2018-09-30 13F CORCEPT THERAPEUTICS COM 218352102 16,077 -782 -4.64 226 -14.72 0.0011
2018-08-10 2018-06-30 13F CORCEPT THERAPEUTICS COM 218352102 16,859 16,859 265 0.0014
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.